bioprognos

HRN: _____

ID Card: _____

OncoBREAST Dx - Order Form

Biochemistry

General:	☒ Creatinine	☒ ASAT	☒ ALAT
	☒ GGT	☒ Total Bilirubin	
Serum Tumor Markers:	☒ CA 15.3	☒ CEA	☒ EGFR
	☒ NGAL	☒ NSE	☒ 8-OHdG

Anamnesis

Personal Data

Age (years): _____

Comorbidities

Atherosclerosis	☐ Yes	☐ No	☐ Unknown
Chronic Liver Disease:	☐ Yes	☐ No	☐ Unknown
Diabetes Mellitus 1 or 2	☐ Yes	☐ No	☐ Unknown
Jaundice:	☐ Yes	☐ No	☐ Unknown
Renal Failure:	☐ Yes	☐ No	☐ Unknown

Lifestyle

Smoking:	☐ Never	☐ Currently	☐ Past
	☐ Unknown		

Order Information

Ordered by: _____ Signature: _____

Order Date: _____

Disclaimer

According to Annex VII of Medical Device Directive 93/42/EEC, Class I, Rule 12, OncoBREAST Dx is a non-invasive blood and urine test useful to suggest a possible diagnosis in women with suspected malignancy in the breast, reduce inappropriate diagnostic tests, days of hospitalization, as well as morbidity. It is specially designed for women with a suspicious lump found in the breast, as a complementary method in radiological testing for high-risk women or those with a level of BI-RADS 3 and 4A (image findings suspicious of Breast Cancer that should be biopsied to verify malignancy), as well as women with family history of Breast Cancer.

OncoBREAST Dx is based in a panel consisting of 6 serum Tumor Markers (CA 15.3, CEA, EGFR, NGAL, NSE and 8-OHdG), as well as clinical data to obtain the best performance (Sensitivity of 82.3% and Specificity of 85.7%), by reducing the number of false positives generated by benign comorbidities and other well-known causes.

Bioprognos SL
Benet Mateu, 40 - 08034 Barcelona (Spain)
Email: info@bioprognos.com
Website: www.bioprognos.com

V.4 Rev.001

CE